Compare · RCKT vs RKT
RCKT vs RKT
Side-by-side comparison of Rocket Pharmaceuticals Inc. (RCKT) and Rocket Companies Inc. (RKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- RCKT operates in Health Care, while RKT operates in Finance - the two are in different parts of the market.
- RKT is the larger of the two at $34.40B, about 103.8x RCKT ($331.5M).
- Over the past year, RCKT is down 15.8% and RKT is down 37.4% - RCKT leads by 21.6 points.
- RKT has been more active in the news (27 items in the past 4 weeks vs 6 for RCKT).
- Both have 25 recent analyst ratings on file.
- Company
- Rocket Pharmaceuticals Inc.
- Rocket Companies Inc.
- Price
- $2.69-10.61%
- $11.93-1.65%
- Market cap
- $331.5M
- $34.40B
- 1M return
- -28.61%
- -16.63%
- 1Y return
- -15.78%
- -37.42%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2020
- News (4w)
- 6
- 27
- Recent ratings
- 25
- 25
Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Rocket Companies Inc.
Rocket Companies, Inc. engages in the tech-driven real estate, mortgage, and eCommerce businesses in the United States and Canada. It operates in two segments, Direct to Consumer and Partner Network. The company's solutions include Rocket Mortgage, a mortgage lender; Amrock that provides title insurance, property valuation, and settlement services; Rocket Homes, a home search platform and real estate agent referral network, which offers technology-enabled services to support the home buying and selling experience; Rocket Auto, an automotive retail marketplace that provides centralized and virtual car sales support to national car rental and online car purchasing platforms; and Rocket Loans, an online-based personal loans business. Its solutions also include Core Digital Media, a digital social and display advertiser in the mortgage, insurance, and education sectors; Nexsys, a fintech company, which offers a suite of essential tech solutions for mortgage origination and closing processes through digitization and automation; Lendesk, a technology services company that provides a point of sale system for mortgage professionals and a loan origination system for private lenders; and Edison Financial, a digital mortgage startup. In addition, the company originates, closes, sells, and services agency-conforming loans. Rocket Companies, Inc. was founded in in 1985 and is headquartered in Detroit, Michigan. Rocket Companies, Inc. is a subsidiary of Rock Holdings, Inc.
Latest RCKT
- Rocket Pharmaceuticals upgraded by Needham with a new price target
- General Counsel Wilson Martin sold $256,464 worth of shares (75,364 units at $3.40), decreasing direct ownership by 11% to 598,489 units (SEC Form 4) (withholding tax)
- Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
- Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
- Chardan Capital Markets resumed coverage on Rocket Pharmaceuticals with a new price target
- Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- General Counsel Wilson Martin sold $2,133 worth of shares (631 units at $3.38), decreasing direct ownership by 0.09% to 673,853 units (SEC Form 4) to cover withholding tax
- CEO Shah Gaurav sold $7,753 worth of shares (2,293 units at $3.38), decreasing direct ownership by 0.22% to 1,056,594 units (SEC Form 4) (for tax liability)
- CEO Shah Gaurav sold $9,592 worth of shares (2,837 units at $3.38), decreasing direct ownership by 0.27% to 1,058,887 units (SEC Form 4) to cover withholding tax
Latest RKT
- Rover and Redfin Unleash New Guide on Canada's Best Cities for Dog Walks
- Rover and Redfin Unleash New Guide on America's Best Cities for Dog Walks
- Redfin Reports U.S. Home Prices Rose 0.25% From a Month Earlier in August
- Nearly Half of Homebuyers Get Concessions From Sellers as Most Markets Tip in Buyers' Favor
- Redfin Reports Pending Home Sales Dip to Lowest Level in Nearly 3 Years
- Pres & CEO, Rocket Mortgage Bray Jesse K sold $2,949,750 worth of shares (225,000 units at $13.11) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Rocket Companies Inc.
- San Antonio is the Top Destination for Gen Z Movers, While Millennials Favor Houston
- It's Now The Strongest Buyer's Market on Record, Driven by the Sun Belt
- High Costs Sideline Some Would-Be Homebuyers, Handing Upper Hand to Those Who Stay in the Market